Why the study?
Does flosequinan improve cardiopulmonary parameters during submaximal exercise in patients with moderate to severe chronic cardiac failure?
Population
20 patients with moderate to severe chronic cardiac failure
Comparison
Flosequinan 100 mg daily for 8 weeks vs Matching placebo
Design
RCT, double-blind
Follow-up
8 weeks
Authors
Loading...
Flosequinan improves submaximal exercise capacity in chronic cardiac failure; confirms cardiopulmonary benefit in RCT and supports larger outcome trials.
Does flosequinan improve cardiopulmonary parameters during submaximal exercise in patients with moderate to severe chronic cardiac failure?
Flosequinan improves submaximal exercise performance in patients with chronic cardiac failure, likely by enhancing skeletal muscle blood flow.
Elborn et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: